These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 39250493

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Utility of the combination of DAT SPECT and MIBG myocardial scintigraphy in differentiating dementia with Lewy bodies from Alzheimer's disease.
    Shimizu S, Hirao K, Kanetaka H, Namioka N, Hatanaka H, Hirose D, Fukasawa R, Umahara T, Sakurai H, Hanyu H.
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):184-192. PubMed ID: 26233438
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies.
    McCleery J, Morgan S, Bradley KM, Noel-Storr AH, Ansorge O, Hyde C.
    Cochrane Database Syst Rev; 2015 Jan 30; 1(1):CD010633. PubMed ID: 25632881
    [Abstract] [Full Text] [Related]

  • 5. The usefulness of combined brain perfusion single-photon emission computed tomography, Dopamine-transporter single-photon emission computed tomography, and 123 I-metaiodobenzylguanidine myocardial scintigraphy for the diagnosis of dementia with Lewy bodies.
    Kobayashi S, Makino K, Hatakeyama S, Ishii T, Tateno M, Iwamoto T, Tsujino H, Kawasaki K, Mikuni K, Ukai W, Murayama T, Hashimoto E, Utsumi K, Kawanishi C.
    Psychogeriatrics; 2017 Jul 30; 17(4):247-255. PubMed ID: 28130808
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study.
    McKeith I, O'Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C, DLB Study Group.
    Lancet Neurol; 2007 Apr 30; 6(4):305-13. PubMed ID: 17362834
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neuroimaging for diagnosing dementia with Lewy bodies: What is the best neuroimaging technique in discriminating dementia with Lewy bodies from Alzheimer's disease?
    Shimizu S, Kanetaka H, Hirao K, Fukasawa R, Namioka N, Hatanaka H, Hirose D, Umahara T, Sakurai H, Hanyu H.
    Geriatr Gerontol Int; 2017 May 30; 17(5):819-824. PubMed ID: 27138074
    [Abstract] [Full Text] [Related]

  • 9. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT.
    Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, Barber C, Carter J, Walker Z.
    J Neurol Neurosurg Psychiatry; 2012 Nov 30; 83(11):1063-70. PubMed ID: 22869921
    [Abstract] [Full Text] [Related]

  • 10. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study.
    van der Zande JJ, Joling M, Happach IG, Vriend C, Scheltens P, Booij J, Lemstra AW.
    Neuroimage Clin; 2020 Nov 30; 25():102062. PubMed ID: 31790878
    [Abstract] [Full Text] [Related]

  • 11. The utility of the combined use of 123I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes.
    Matsusue E, Fujihara Y, Tanaka K, Aozasa Y, Shimoda M, Nakayasu H, Nakamura K, Ogawa T.
    Acta Radiol; 2019 Feb 30; 60(2):230-238. PubMed ID: 29804474
    [Abstract] [Full Text] [Related]

  • 12. Utility of combining multiple parameters of 123I-IMP SPECT and voxel-based morphometry MRI using a multiparametric scoring system for differentiating dementia with Lewy bodies from Alzheimer's disease.
    Matsusue E, Inoue C, Shimoda M, Nakamura T, Matsumoto S, Matsumoto K, Tanino T, Nakamura K, Fujii S.
    Acta Radiol; 2024 Jul 30; 65(7):825-834. PubMed ID: 38785068
    [Abstract] [Full Text] [Related]

  • 13. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies.
    O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG.
    Arch Neurol; 2004 Jun 30; 61(6):919-25. PubMed ID: 15210531
    [Abstract] [Full Text] [Related]

  • 14. Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An 123I-FP-CIT SPECT study.
    Joling M, Vriend C, Raijmakers PGHM, van der Zande JJ, Lemstra AW, Berendse HW, Booij J, van den Heuvel OA.
    Neuroimage Clin; 2019 Jun 30; 22():101755. PubMed ID: 30884365
    [Abstract] [Full Text] [Related]

  • 15. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy.
    Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL.
    J Neurol Neurosurg Psychiatry; 2007 Nov 30; 78(11):1176-81. PubMed ID: 17353255
    [Abstract] [Full Text] [Related]

  • 16. Cingulate island sign on FDG-PET is associated with medial temporal lobe atrophy in dementia with Lewy bodies.
    Iizuka T, Kameyama M.
    Ann Nucl Med; 2016 Jul 30; 30(6):421-9. PubMed ID: 27098829
    [Abstract] [Full Text] [Related]

  • 17. Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.
    Soret M, Koulibaly PM, Darcourt J, Buvat I.
    Eur J Nucl Med Mol Imaging; 2006 Sep 30; 33(9):1062-72. PubMed ID: 16639610
    [Abstract] [Full Text] [Related]

  • 18. Differential diagnosis of dementia with Lewy Bodies and Alzheimer Disease using combined MR imaging and brain perfusion single-photon emission tomography.
    Goto H, Ishii K, Uemura T, Miyamoto N, Yoshikawa T, Shimada K, Ohkawa S.
    AJNR Am J Neuroradiol; 2010 Apr 30; 31(4):720-5. PubMed ID: 20075101
    [Abstract] [Full Text] [Related]

  • 19. [DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease].
    Vaamonde-Gamo J, Flores-Barragán JM, Ibáñez R, Gudín M, Hernández A.
    Rev Neurol; 2010 Apr 30; 41(5):276-9. PubMed ID: 16138284
    [Abstract] [Full Text] [Related]

  • 20. Imaging of the nigrostriatal system for evaluating the preclinical phase of Parkinson's disease development: the utility of neuromelanin, diffusion MRI, and DAT-SPECT.
    Takahashi H, Kashiwagi N, Arisawa A, Matsuo C, Kato H, Adachi H, Kajiyama Y, Mochizuki H, Tomiyama N.
    Br J Radiol; 2022 Feb 01; 95(1130):20210837. PubMed ID: 34808066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.